Instrument Inactif

Communiqués Unigene Laboratories Inc

Actions

Produits pharmaceutiques

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

Communiqués

14/05/13	Unigene Laboratories Inc : Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update	PU
09/05/13	Unigene Laboratories Inc : Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs	PU
18/04/13	Unigene Laboratories Inc : Victory Park Capital Completes Public Auction of Unigene’s Peptelligence™ Drug Delivery Platform	PU
08/04/13	Unigene Laboratories : Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization – Victory Park Capital Commences Process for Potential Sale of PeptelligenceTM Drug Delivery Platform	PU
12/03/13	Unigene Laboratories Inc : Unigene Announces Fourth Quarter and Full-Year 2012 Results	PU
06/03/13	Unigene Laboratories Inc : Unigene Comments on FDA Advisory Committee Review of Salmon Calcitonin	PU
13/02/13	Unigene Laboratories Inc : UNIGENE RECEIVES 2013 DRUG DELIVERY PARTNERSHIPS	PU
07/02/13	Unigene Laboratories Inc : Unigene to Present at the 17th Annual Drug Delivery Partnerships Meeting	PU
01/02/13	Unigene Laboratories Inc : Unigene Completes Financial Statement Amendment	PU
15/01/13	Unigene Laboratories Inc : Unigene Welcomes FDA Advisory Committee Review of Salmon Calcitonin	PU
12/12/12	Unigene Laboratories Inc : Unigene’s Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone	PU
11/12/12	Unigene Laboratories Inc : Unigene Engages Financial Advisor to Explore Strategic Options and Advance Corporate Objectives	PU
27/11/12	Unigene Laboratories Inc : UNIGENE AND TARIX PHARMACEUTICALS ENTER DEFINITIVE LICENSING AGREEMENT FOR “PEPTELLIGENCE-ENGINEERED” TXA127	PU
20/11/12	Unigene Laboratories Inc : Unigene Announces Third Quarter 2012 Corporate Update	PU
16/11/12	Unigene Laboratories Inc : Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012	PU
16/10/12	Unigene Laboratories : Unigene’s Licensee, Tarsa Therapeutics, Reports Positive Clinical Data in Phase 2 Study of Oral Calcitonin for Prevention of Postmenopausal Osteoporosis	PU
26/09/12	Unigene Laboratories : Unigene to Target Partnering and Therapeutic Development Opportunities Following Victory Park Capital Debt Financing and Forbearance	PU
19/09/12	Unigene Laboratories : UNIGENE AND TARIX PHARMACEUTICALS REPORT HIGHLY INCREASED ORAL BIOAVAILABILITY OF “PEPTELLIGENCE-ENGINEERED” TXA127	PU
15/08/12	Unigene Laboratories : UNIGENE AND NORDIC BIOSCIENCE ANNOUNCE PRELIMINARY SELECTION OF LEAD COMPOUND FOR TREATING TYPE 2 DIABETES	PU
04/06/12	Unigene Laboratories : Unigene Enters Agreement to Eliminate 1/3 of its Outstanding $67MM Debt	PU
22/05/12	Unigene Laboratories : Unigene’s Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies	PU
21/05/12	Unigene Laboratories : Unigene to Present at TIDES 2012	PU
02/04/12	Unigene Laboratories : UNIGENE APPOINTS JACK WYSZOMIERSKI TO ITS BOARD OF DIRECTORS	PU
29/03/12	Unigene Laboratories : UNIGENE TO PRESENT AT THE 11TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE	PU
22/03/12	Unigene Laboratories : SUPREME COURT DENIES APOTEX’S PETITION FOR A WRIT OF CERTIORARI	PU